MR引导放疗对食管癌患者剂量学获益的模拟评估
结果显示MRgRT在不牺牲靶区覆盖的前提下显著降低危及器官剂量,其局部加量方案可使危及器官剂量与常规IGRT方案大致相当。
要点
- MRgRT在不牺牲靶区覆盖的前提下显著降低心脏和肺的剂量。
- 平均肺剂量降低28%,肺V20Gy降低55%。
- 平均心脏剂量降低24%,心脏V25Gy降低53%、V40Gy降低69%。
核心结论
- MRgRT用于食管癌可显著降低心脏和肺的剂量。
- 在线高精度靶向原发肿瘤为局部加量策略、改善局部管理结局提供了新前景。
研究设计与样本
- 整合治疗期间每周获取的5次MRI所反映的分次间和分次内变化,评估每种方案的总累积剂量。
主要发现
- MRgRT方案在所有剂量体积直方图(DVH)参数上均观察到危及器官剂量显著降低,且未牺牲靶区覆盖。
- 平均肺剂量从7.9 Gy降至5.7 Gy,降低28%;肺V20Gy从6.3%降至2.8%,降低55%。
- 平均心脏剂量从14.8 Gy降至11.2 Gy,降低24%;心脏V25Gy从14.3%降至6.7%,降低53%;心脏V40Gy从3.9%降至1.2%,降低69%。
- 原发肿瘤加量至处方剂量66%的MRgRT剂量递增方案,其危及器官剂量与常规IGRT方案大致相当。
临床怎么用
- 食管癌放疗可考虑采用在线MRgRT以降低心脏和肺的累积剂量。
- 在线高精度靶向原发肿瘤可支持局部加量策略的探索,但需注意加量至处方剂量66%时危及器官剂量与常规IGRT大致相当。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the dosimetric benefits of online MR-guided radiotherapy (MRgRT) for esophageal cancer patients and to assess how these benefits could be translated into a local boosting strategy to improve future outcomes. METHODS: Twenty-nine patients were in-silico treated with both a MRgRT regimen and a conventional image guided radiotherapy (IGRT) regimen using dose warping techniques. Here, the inter and intrafractional changes that occur over the course of treatment (as derived from 5 MRI scans that were acquired weekly during treatment) were incorporated to assess the total accumulated dose for each regimen. RESULTS: A significant reduction in dose to the organs-at-risk (OARs) was observed for all dose-volume-histogram (DVH) parameters for the MRgRT regimen without concessions to target coverage compared to the IGRT regimen. The mean lung dose was reduced by 28%, from 7.9 to 5.7 Gy respectively and V20Gy of the lungs was reduced by 55% (6.3-2.8%). A reduction of 24% was seen in mean heart dose (14.8-11.2 Gy), while the V25Gy of the heart was decreased by 53% (14.3-6.7%) and the V40Gy of the heart was decreased by 69% (3.9-1.2%). In addition, MRgRT dose escalation regimens with a boost up to 66% of the prescription dose to the primary tumor yielded approximately the same dose levels to the OARs as from the conventional IGRT regimen. CONCLUSION: This study revealed that MRgRT for esophageal cancer has the potential to significantly reduce the dose to heart and lungs. In addition, online high precision targeting of the primary tumor opens new perspectives for local boosting strategies to improve outcome of the local management of this disease.
引用
- Boekhoff M, Defize I, Borggreve A, et al. An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients. Radiother Oncol. 2021. PMID: 34237345. doi:10.1016/j.radonc.2021.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。